Pulsed-Field Ablation Safety Signal: Rare Fatal Arrhythmias in the Era of “Safer” AF Ablation

Pulsed-field ablation (PFA) has rapidly transformed atrial fibrillation ablation due to its tissue selectivity and reduced collateral injury, but emerging real-world data raise concern for rare fatal arrhythmic events.

Initial enthusiasm was driven by near elimination of atrio-esophageal fistula, phrenic nerve injury, and pulmonary vein stenosis, positioning PFA as a safer alternative to thermal ablation.

Recent MAUDE-based analyses highlight a potential signal of early malignant ventricular arrhythmias, often occurring intra-procedurally or within hours, contrasting with esophageal complications seen in thermal modalities.

Estimated mortality remains extremely low but may be higher with PFA vs thermal ablation (≈17.8 vs 8.6 per 100,000), with arrhythmic death emerging as a distinct mechanism rather than thermal injury.

Mechanisms remain unclear, with hypotheses including coronary vasospasm, myocardial electrical instability, or energy–tissue interaction variability, and importantly, no established prevention strategies.

Interpretation is limited by MAUDE reporting bias, underreporting, and denominator uncertainty, yet consistent expert consensus suggests this is a signal worth investigation, not dismissal.

Clinical Takeaway: PFA remains highly effective and overall safe, but clinicians should recognize early arrhythmic risk, consider post-procedural monitoring, and incorporate this into informed consent discussions.

Practice Points
- Recognize arrhythmic death as a rare but unique complication of PFA
- Maintain vigilance for early post-procedural ventricular arrhythmias
- Consider extended telemetry monitoring in higher-risk patients
- Balance reduced thermal injury risk against emerging electrical complications
- Emphasize shared decision-making with updated risk counseling

Patient Scenario
A 68-year-old male with persistent AF undergoes PFA-based PVI and develops polymorphic VT within hours post-procedure.

Step	Change in Management
Monitoring	Extend telemetry beyond standard recovery window
Evaluation	Assess for coronary spasm, electrolyte imbalance
Prevention	Consider protocolized post-PFA observation pathways

References
Tilz RR. TIFFANY Study. HRS 2026.
MANIFEST-US Registry.
EMBOL-AF Study.
FDA MAUDE Database analyses.